Search Results
Your search for 3 matches 15281 pages
Showing 2601 - 2650Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer: Clinical Implications of Residual Cancer Burden
An exploratory analysis of KEYNOTE-522, which established the benefit of neoadjuvant pembrolizumab plus chemotherapy in triple-negative breast cancer, has now provided data to further describe prognosis and possibly guide treatment.1 In the study, presented at the 2022 ASCO Annual Meeting,...
Study Finds Patritumab Deruxtecan Active in HER3-Expressing Metastatic Breast Cancer
The HER3-directed antibody-drug conjugate patritumab deruxtecan (HER3-DXd) showed activity in patients with heavily pretreated HER3-expressing metastatic breast cancer in a phase I/II study. Ian E. Krop, MD, PhD, Associate Director, Yale Cancer Center, New Haven, Connecticut, presented these...
Addition of Neoadjuvant Nivolumab to Chemotherapy Improves Complete Pathologic Response Rate and Event-Free Survival in Resectable NSCLC
As reported in The New England Journal of Medicine by Patrick M. Forde, MB, BCh, of Johns Hopkins Kimmel Cancer Center, and colleagues, the phase III CheckMate 816 trial has shown improved pathologic complete response rate and event-free survival with the addition of nivolumab to platinum-based...
Selpercatinib Approved for Advanced RET Fusion–Positive Solid Tumors and Advanced RET Fusion–Positive NSCLC
On September 21, 2022, selpercatinib was granted accelerated approval for adults with locally advanced or metastatic solid tumors with RET gene fusion whose disease has progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options.1 On the same day,...
Capturing Tumor Evolution With Serial Biopsies May Guide Treatment Changes to Benefit Patients With Breast Cancer
Molecular testing and genomic testing are now considered standard of care in breast cancer, guiding treatment decisions in early breast cancer and targeted therapies in the metastatic setting. “But tumors evolve,” Virginia Kaklamani, MD, DSc, reminded participants at the 2022 Lynn Sage Breast...
Study Finds Use of Remote Interventions Improved Adherence to Cancer Screenings Among Women Living in Rural Areas
Remote interventions, particularly a mailed tailored DVD plus telephonic patient navigation, improved adherence to breast, cervical, and colorectal cancer screenings among women living in rural counties in the United States, according to the results of a randomized controlled clinical trial...
Addition of First-Line Atezolizumab to Vemurafenib/Cobimetinib in BRAF V600–Mutant Advanced Melanoma
As reported in The Lancet Oncology by Paolo A. Ascierto, MD, and colleagues, the second interim overall survival analysis of the phase III IMspire150 trial has shown a numeric but statistically nonsignificant improvement with the addition of first-line atezolizumab to vemurafenib and cobimetinib in ...
Addition of Daratumumab to Bortezomib Plus Dexamethasone in Relapsed or Refractory Multiple Myeloma: CASTOR Trial Final Overall Survival Analysis
As reported in the Journal of Clinical Oncology by Sonneveld et al, the final overall survival analysis of the phase III CASTOR trial has shown a significant overall survival benefit with daratumumab plus bortezomib/dexamethasone (D-Vd) vs bortezomib/dexamethasone alone (Vd) in patients with...
Silicone Film Dressing May Reduce Acute Radiation Dermatitis in Some Patients With Breast Cancer
A silicone-based polyurethane film dressing (known as Mepitel® Film) appears to be beneficial in reducing skin toxicities caused by radiation treatment, according to data presented during the October 2022 ASCO Plenary Series.1 The results of a phase III trial showed that this film dressing may be...
T-DXd Yields Longer Overall Survival than T-DM1 as Second-Line Treatment in Patients With HER2-Positive Metastatic Breast Cancer: DESTINY-Breast03
Second-line treatment with fam-trastuzumab deruxtecan-nxki (T-DXd) led to significantly longer overall survival compared with ado-trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer, according to updated results from the DESTINY-Breast03 phase III clinical trial...
Neoadjuvant T-DXd Shows Clinical Activity in Patients With HER2-Low Breast Cancer
Patients with localized, hormone receptor (HR)-positive, HER2-low breast cancer treated with fam-trastuzumab deruxtecan-nxki (T-DXd) in the neoadjuvant setting had an overall response rate of 75% without combining the agent with anastrozole and 63% in combination with anastrozole, according to...
NRG/RTOG 1112: Radiotherapy Added to Sorafenib Improves Survival in Advanced Hepatocellular Carcinoma
Stereotactic body radiation therapy (SBRT) given prior to sorafenib improved overall survival, progression-free survival, and time to disease progression in patients with unresectable advanced hepatocellular cancer vs sorafenib alone, including those with macrovascular invasion, according to the...
Cancer Drugs and Price Controls: Is It Time?
According to a recent article published in Cancer Epidemiology, Biomarkers & Prevention, cancer care in the United States exceeded $208 billion in 2020 and is expected to surpass $240 billion by 2030.1 These estimates are driven largely by a growing and aging population. The expenditures...
How the Pancreatic Cancer Early Detection Consortium Aims to Advance Survival Rates in This Deadly Disease
The statistics are grim: Worldwide, pancreatic cancer is the 12th most common cancer and the seventh leading cause of cancer mortality.1 In the United States, the malignancy has the highest mortality rate of all major cancers. It is currently the third leading cause of cancer-related death after...
Expert Point of View: Sophia C. Kamran, MD
Formal discussant of the PCS5 trial, Sophia C. Kamran, MD, Director of Diversity, Equity, and Inclusion, Department of Radiation Oncology at Massachusetts General Hospital and Assistant Professor of Radiation Oncology at Harvard Medical School, said the goal of trials like this one is to optimize...
PCS5 Trial: 5 Weeks of Radiation Therapy May Be Equivalent to 8 Weeks in High-Risk Prostate Cancer
According to the results of the phase III randomized Prostate Cancer Study 5 (PCS5), a noninferior trial, 5 weeks of radiation therapy may be equivalent to 8 weeks for men with high-risk prostate cancer on androgen-deprivation therapy. These findings were presented at the 2022 American Society for...
Adjuvant Pembrolizumab May Improve Quality of Life in Patients With High-Risk Resected Melanoma
Taken together with the primary clinical results, a secondary analysis of the phase III SWOG S1404 randomized clinical trial demonstrated that pembrolizumab provides superior clinical and patient-reported quality-of-life outcomes compared to standard of care with adjuvant ipilimumab or high-dose...
Lu-177 Vipivotide Tetraxetan Shows Benefit in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer
On December 5, Novartis announced the pivotal phase III PSMAfore study of lutetium (Lu-177) vipivotide tetraxetan, a prostate-specific membrane antigen (PSMA)-targeted radioligand therapy, met its primary endpoint. The therapy demonstrated a statistically significant and clinically meaningful...
Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors
In the phase Ib/II JAVELIN PARP Medley trial reported in JAMA Oncology, Timothy A. Yap, MBBS, PhD, and colleagues found that the combination of the anti–PD-L1 agent avelumab and the poly (ADP-ribose) polymerase (PARP) inhibitor talazoparib produced objective response rates in patient subgroups with ...
DNA Repair Protein MRE11 Expression and Disease-Specific Mortality Among Patients With Muscle-Invasive Bladder Cancer Receiving Trimodality Therapy
In a retrospective analysis reported in JAMA Network Open, Magliocco et al found that among patients with muscle-invasive bladder cancer receiving bladder-preserving trimodality therapy, those with a lower expression of the DNA repair protein MRE11 had significantly poorer disease-specific...
ELIANA Trial 3-Year Update: Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed or Refractory B-Cell ALL
As reported in the Journal of Clinical Oncology by Laetsch et al, the 3-year update of the phase II ELIANA trial showed durable responses and a manageable safety profile with tisagenlecleucel for the treatment of pediatric and young adult patients with relapsed or refractory B-cell acute...
Roger Li, MD, on Bladder Cancer: Boosting Immune Checkpoint Blockade With an Oncolytic Adenovirus
Roger Li, MD, of the H. Lee Moffitt Cancer Center, discusses results from a phase II single-arm study of CG0070, a cancer-selective oncolytic adenovirus that creates mechanistic synergy with immune checkpoint blockade. In this trial, the virus was combined with pembrolizumab in patients with...
Risk of Cancer May Double for Patients With ‘Skewed’ Blood Cells
New research has shed light on how skewed X chromosome inactivation may be linked to the development of cancer and cardiovascular disease, according to a novel study published by Roberts et al in eLife. Background Because the X chromosome has so many more genes than the Y chromosome, in every cell...
Are Patients Older Than 65 Years Being Overscreened for Cervical Cancer?
Patients older than 65 years may be undergoing unnecessary cervical cancer screenings, and more public health data may be needed on the utilization of cervical cancer screening–associated services among older patients to prevent potential harm and unnecessary costs, according to a new study...
Autologous Tumor Lysate–Loaded Dendritic Cell Vaccine for Glioblastoma
In an externally controlled phase III trial reported in JAMA Oncology, Liau et al found that the addition of an autologous tumor lysate–loaded dendritic cell vaccine (DCVax-L) to standard of care improved survival in patients with newly diagnosed glioblastoma and recurrent glioblastoma compared...
Ethnic Diversity and Disparities in Access to Genetic Testing May Impact Prostate Cancer Development and Treatment, Research Shows
More than 1.4 million patients were diagnosed with prostate cancer in 2020 globally, but the molecular characteristics of the disease remain unexplored for the majority of patients around the world. In the final days of the Movember campaign, which every year in November aims to raise awareness of...
Novel Bispecific Antibody Zanidatamab in Advanced HER2-Expressing or HER2-Amplified Cancers
In a phase I dose-escalation and expansion study reported in The Lancet Oncology, Funda Meric-Bernstam, MD, and colleagues found that zanidatamab, a novel bispecific monoclonal antibody directed against two nonoverlapping domains of HER2, showed activity in locally advanced or metastatic...
Potential Factors in Oxaliplatin-Induced Peripheral Neuropathy in Patients With Stage III Colon Cancer
In an analysis from the phase III CALGB (Alliance)/SWOG 80702 trial of adjuvant FOLFOX (fluorouracil, leucovorin, and oxaliplatin) for patients with stage III colon cancer reported in the Journal of Clinical Oncology, Lee et al found that longer duration of oxaliplatin treatment was associated with ...
T-DXd in Pretreated Patients With HER2-Low Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
As reported in the Journal of Clinical Oncology by Yamaguchi et al, an exploratory cohort analysis in a Japanese/South Korean phase II trial (DESTINY-Gastric01) indicated that fam-trastuzumab deruxtecan-nxki (TDX-d) showed activity in previously treated—but anti-HER2 treatment–naive—patients with...
Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors
As reported in JAMA Oncology by Schram et al, the phase IIb tumor-agnostic JAVELIN BRCA/ATM trial has shown that the combination of avelumab and talazoparib did not meet the prespecified objective response rate goal among patients with advanced BRCA1/2-altered or ATM-altered solid tumors. The...
Zanubrutinib vs Ibrutinib in Relapsed or Refractory CLL
In an interim analysis of the phase III ALPINE trial reported in the Journal of Clinical Oncology, Peter Hillmen, MBChB, PhD, and colleagues found that zanubrutinib produced a significantly higher objective response rate vs ibrutinib in patients with relapsed or refractory chronic lymphocytic...
Effect of Geriatric Assessment Intervention on Patient-Reported Symptomatic Toxicity in Patients Aged 70 and Older Receiving Treatment for Advanced Cancer
In a secondary analysis of the Geriatric Assessment for Patients 70 Years and Older (GAP70+) trial reported in the Journal of Clinical Oncology, Eva Culakova, PhD, MS, and colleagues found that providing geriatric assessment–based recommendations to community oncologists was associated with reduced ...
5-Year Outcomes With Stereotactic Ablative Body Radiotherapy for Primary Renal Cell Carcinoma
In an individual patient meta-analysis reported in The Lancet Oncology, Shankar Siva, PhD, and colleagues found that patients receiving stereotactic ablative body radiotherapy (SABR) for primary localized renal cell carcinoma had long-term outcomes indicating that the treatment is safe and...
Report on Brain Cancer: Crisis in the Childhood and Adolescent Cancer Community
A RECENT REPORT published in Neuro-Oncology1 exposes an alarming reality for children, adolescents, and families facing pediatric brain cancer across the country. The Pediatric Brain Tumor Foundation (PBTF) funded this groundbreaking report by the Central Brain Tumor Registry of the United States...
Annual Report to the Nation: Cancer Deaths Continue Downward Trend
OVERALL CANCER death rates continued to decline among men, women, children, and adolescents/young adults in every major racial and ethnic group in the United States from 2015 to 2019, according to the latest Annual Report to the Nation on the Status of Cancer.1 From 2014 to 2018, the overall cancer ...
C.S. Pramesh, MS, FRCS, Seeks to Bring Equity to India’s Sprawling Cancer Care System
In this installment of The ASCO Post’s Living a Full Life series, Guest Editor Jame Abraham, MD, FACP, spoke with C.S. Pramesh, MS, FRCS, Director of the Tata Memorial Hospital and Professor and Head of Thoracic Surgery at the Tata Memorial Centre, Mumbai, India. Dr. Pramesh is the Convener of the...
FDA Grants Accelerated Approval to Teclistamab-cqyv for Resistant Myeloma
On October 25, 2022, the U.S. Food and Drug Administration (FDA) granted accelerated approval to teclistamab-cqyv (Tecvayli), the first bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager, for adults with relapsed or refractory multiple myeloma who have received at least four...
ASCO Publishes Rapid Guideline Update on PARP Inhibitors in Ovarian Cancer
An ASCO guideline rapid update is revising guidance for the use of poly (ADP-ribose) polymerase (PARP) inhibitor therapy for the management of ovarian cancer to include updated considerations for the use of several different PARP inhibitor therapies based on recent phase III clinical trial data.1...
Expert Point of View: Sanjay Popat, FRCP, PhD
“Adjuvant osimertinib has been adopted widespread as a standard of care as a result of the primary results of ADAURA,” said formal discussant Sanjay Popat, FRCP, PhD, medical oncologist and lung specialist at the Royal Marsden Hospital, NHS Foundation Trust, London. “We have more granularity about ...
Longer-Term Follow-up From ADAURA Supports Adjuvant Osimertinib as Standard of Care for EGFR-Mutated Stage IB to IIIA NSCLC
With longer-term follow-up, adjuvant treatment with osimertinib led to a 77% reduction in the risk of disease recurrence or death following complete resection vs placebo-treated patients with EGFR-mutated, stage II to IIIA non–small cell lung cancer (NSCLC). Disease-free survival was improved...
Chronic Myelomonocytic Leukemia: Treatment and Prognosis, Part 1
The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In this installment, Drs. Syed Ali Abutalib and Mrinal M. Patnaik explore the current treatment and prognosis of chronic myelomonocytic leukemia. For each quiz question...
Building a New Normal: Symptom Self-Management Intervention May Benefit Cancer Survivors
An easy-to-deploy, automated self-management intervention may prove to be of benefit in supporting competence and symptom management among cancer survivors, according to data presented during the 2022 ASCO Quality Care Symposium.1 Analysis of the randomized controlled trial found that 12 months...
Trastuzumab Deruxtecan for Advanced HER2-Low Breast Cancer
On August 5, 2022, fam-trastuzumab deruxte-can-nxki was approved for patients with unresectable or metastatic HER2-low (immunohistochemistry [IHC] 1+ or IHC 2+/in situ hybridization–negative) breast cancer who have received prior chemotherapy in the metastatic setting or developed disease...
Personalized Breast Cancer Screening Model May Improve Outcomes and Reduce Overdiagnosis
Researchers have created a model for predicting an individual’s breast cancer risk that could be used to create personalized breast cancer screening strategies, according to a new study published by Louro et al in the European Journal of Cancer. The research, also presented at the 13th European...
Expert Point of View: Fabrice André, MD, PhD
Fabrice André, MD, PhD, Professor of Medical Oncology at the Gustave Roussy Cancer Center, Villejuif, France, and Chairman of the Biomarker Group at UNICANCER, provided comments on the stage IIA cohort of the PALLAS trial. “The key message from PALLAS1 is there is no signal for efficacy of...
PALLAS Trial: No Benefit Reported for Adjuvant Palbociclib in Stage IIA Hormone Receptor–Positive, HER2-Negative Breast Cancer
In a preplanned analysis of the stage IIA cohort of the PALLAS trial, the addition of adjuvant palbociclib to standard endocrine therapy did not improve outcomes over endocrine therapy alone. This finding suggests this agent provides no benefit in reducing the risk of early relapse in patients with ...
Short Course of Radiotherapy With Concurrent Radiation Boost for High-Risk, Early-Stage Breast Cancer
A 3-week course of radiation therapy including a concomitant boost of radiation to the surgical site appears to be as safe and effective as 4 to 6 weeks of radiation therapy given with a sequential boost of radiation for patients with early-stage breast cancer who have a high risk of recurrence....
The NordICC Trial: The Devil Is in the Details
Colorectal cancer ranks third among cancer deaths in both men and women in the United States, with an estimated 150,000 new cases and 52,000 deaths anticipated in 2022.1 Colorectal cancer rates have declined by approximately 2% per year from 2014 to 2018 in people older than age 50, which is...
How ASCO Is Helping Members Navigate the Cancer Care Terrain for Pregnant Patients Since the Reversal of Roe v Wade
In response to the U.S. Supreme Court decision in Dobbs v Jackson Women’s Health Organization overturning Roe v Wade, eliminating the constitutional right to an abortion and returning the power to regulate reproductive health for women to the states, ASCO, the American Cancer Society Action...
Trametinib With or Without Dabrafenib in Pediatric BRAF V600–Mutant Low-Grade Glioma
In a phase I/II study reported in the Journal of Clinical Oncology, Eric Bouffet, MD, and colleagues found that trametinib alone or in combination with dabrafenib was safe and showed activity in pediatric patients with BRAF V600–mutant low-grade glioma. Study Details In the international four-part ...
